Holen Sie sich die Stockscreener-App
1.20
2.13%
0.025
Handel nachbörslich:
1.19
-0.01
-0.83%
Femasys Inc Aktie (FEMY) Neueste Nachrichten
Femasys secures new patent for FemBloc birth control By Investing.com - Investing.com South Africa
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control - GlobeNewswire
Femasys secures new patent for FemBloc birth control - Investing.com
Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed - GlobeNewswire
Femasys Advances in Women’s Health Innovation - TipRanks
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program - GlobeNewswire
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Femasys Receives Second Order from Spain Partners After - GlobeNewswire
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments - StockTitan
Femasys announes infertility clinic customers from coast to coast - TipRanks
Femasys Announces Infertility Clinic Customers from Coast to Coast - GlobeNewswire
H.C. Wainwright maintains Buy rating on Femasys on secureing strategic Spain distribution - Investing.com India
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Femasys secures distribution partnerships for commercialization of FemaSeed - TipRanks
Femasys Secures Strategic Distribution Partnerships for - GlobeNewswire
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market - StockTitan
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device - Yahoo Finance
Items Tagged with 'Femchec' - BioWorld Online
Femasys gains FDA clearance for new diagnostic tool FemChec - Investing.com India
Femasys Femchec receives FDA clearance - BioWorld Online
Femasys gains FDA clearance for new diagnostic tool FemChec By Investing.com - Investing.com UK
Femasys Inc. Receives U.S. FDA Clearance to Market - GlobeNewswire
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check - StockTitan
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting - GlobeNewswire
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI - MSN
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Femasys Inc (FEMY)’s stock price range in the last year - US Post News
Stocks of Femasys Inc (FEMY) are poised to climb above their peers - SETE News
Femasys Releases Updated Corporate Presentation Online - TipRanks
Femasys Inc (FEMY) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Femasys secures CE mark certification for FemVue MINI solution - Yahoo Finance
FEMYFemasys Inc. Latest Stock News & Market Updates - StockTitan
Femasys gains European and Canadian approval for FemVue MINI - Investing.com
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution - GlobeNewswire
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters - GlobeNewswire
Femasys Inc. at August 20th Virtual Investor Summit Microcap Event - StockTitan
Femasys (NASDAQ:FEMY) Stock Quotes, Forecast and News Summary - Benzinga
Chardan Capital Lowers Femasys (NASDAQ:FEMY) Price Target to $10.00 - Defense World
Femasys (NASDAQ:FEMY) PT Lowered to $12.00 at HC Wainwright - Defense World
Femasys Second Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
FEMY’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
0.98%
5.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):